ABBV has reclaimed the narrative after Sunday's Apogee acquisition shock, rallying 5.5% on the week to $234.76 as short sellers extend their retreat and options traders rotate back toward calls.
The short position has continued to shrink since the acquisition announcement. At 25.0 million shares, SI % FF now reads 1.42% — marginally above the June 19 trough but well below the June 15 peak of 25.2 million shares. The 1-week change is a 0.7% decline, extending the pullback that began before the deal was announced. Borrowing costs ticked up 36% on the week to 0.39%, but that number remains trivially low in absolute terms. Availability is effectively unlimited — the borrow pool carries more than 1.4 billion shares available against roughly 25 million short, putting the lending market about as loose as it gets for a large-cap name. There is no squeeze pressure here, and no sign of fresh conviction from bears rebuilding. The short story remains quiet.
Options positioning has flipped meaningfully in AbbVie's favour. The put/call ratio dropped to 0.78, nearly two standard deviations below its 20-day mean of 0.88 — the most call-heavy reading the ratio has produced in several months, and approaching the 52-week low of 0.62. Six weeks ago the PCR was running above 0.94; that defensive overhang has largely unwound. Traders who had been buying puts into the stock's late-May weakness are now leaning the other way.
The Street is reinforcing the bullish tilt. On Tuesday, Canaccord Genuity raised its target from $265 to $273, maintaining its Buy rating, while Piper Sandler reiterated its Overweight with a $298 target — the highest published figure among recent changes. The consensus mean target of $253.83 implies around 8% upside from current levels, a reasonable gap for a large-cap name. Bulls point to Skyrizi and Rinvoq continuing to take share, the Allergan aesthetics business as a durable cash engine, and a forward EPS growth profile that ranks in the 99th percentile of the universe — the company's 12-month forward earnings estimate is rising faster than nearly any comparable stock. Bears counter that the pipeline is acquisitions-heavy rather than organically built, and that the $10.9 billion Apogee deal adds execution risk. The PE of 14.3x and EV/EBITDA of 12.8x are not stretched for a business growing at this rate, though the price-to-book at 117x reflects how little tangible equity sits beneath the franchise value. The dividend score ranks 98th percentile — a reminder that income investors remain a structural buyer of this name.
Among correlated peers, VRTX gained 4.9% on the week, essentially matching ABBV's move and suggesting broad large-cap biotech strength rather than an ABBV-specific re-rating. GILD lagged, down 0.6%, while ARGX added 1.6%. The sector is broadly bid, but ABBV has kept pace with the best of the group.
With Q2 earnings scheduled for July 27, the next five weeks narrow to two questions: whether Skyrizi and Rinvoq can sustain the revenue trajectory that drove the April print 6.9% higher on the day, and how management frames the Apogee integration costs against the forward earnings outlook.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
